Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sulkowski

Showing results (341-350 of 408) with videos related to

Pageof 41
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.
Open Forum Infectious Diseases|May 8, 2026
Non-Hispanic Black Persons With HIV Have a Lower Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease and Clinically Significant Fibrosis Compared to Non-Hispanic White and Hispanic IndividualsTinsay A Woreta, Samer Gawrieh, Laura A Wilson, et al.
Journal of Viral Hepatitis|March 4, 2024
Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugsMark S Sulkowski, Anthony Martinez, Gia L Tyson, et al.
Journal of Viral Hepatitis|December 24, 2017
Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infectionM S Sulkowski, J J Feld, E Lawitz, et al.
Antiviral Therapy|March 8, 2006
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapyVijayan Balan, David R Nelson, Mark S Sulkowski, et al.
The Journal of Clinical Investigation|February 3, 2025
Transcription of hepatitis B surface antigen shifts from cccDNA to integrated HBV DNA during treatmentMaraake Taddese, Tanner Grudda, Giulia Belluccini, et al.
The Lancet. Infectious Diseases|December 10, 2014
Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional studySunil Suhas Solomon, Shruti H Mehta, Aylur K Srikrishnan, et al.
World Journal of Gastroenterology|August 14, 2025
Poor sleep and hepatic steatosis contribute to poorer quality of life in people with human immunodeficiency virusAna N Hyatt, Sai K Kuchana, Eduardo Vilar-Gomez, et al.
Alimentary Pharmacology & Therapeutics|December 29, 2023
Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United StatesSamer Gawrieh, Eduardo Vilar-Gomez, Tinsay A Woreta, et al.
The New England Journal of Medicine|April 1, 2011
Boceprevir for untreated chronic HCV genotype 1 infectionFred Poordad, Jonathan McCone, Bruce R Bacon, et al.
Pageof 41

Showing results (341-350 of 408) with videos related to

Sort By:
Pageof 41
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.
Open Forum Infectious Diseases|May 8, 2026
Non-Hispanic Black Persons With HIV Have a Lower Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease and Clinically Significant Fibrosis Compared to Non-Hispanic White and Hispanic IndividualsTinsay A Woreta, Samer Gawrieh, Laura A Wilson, et al.
Journal of Viral Hepatitis|March 4, 2024
Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugsMark S Sulkowski, Anthony Martinez, Gia L Tyson, et al.
Journal of Viral Hepatitis|December 24, 2017
Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infectionM S Sulkowski, J J Feld, E Lawitz, et al.
Antiviral Therapy|March 8, 2006
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapyVijayan Balan, David R Nelson, Mark S Sulkowski, et al.
The Journal of Clinical Investigation|February 3, 2025
Transcription of hepatitis B surface antigen shifts from cccDNA to integrated HBV DNA during treatmentMaraake Taddese, Tanner Grudda, Giulia Belluccini, et al.
The Lancet. Infectious Diseases|December 10, 2014
Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional studySunil Suhas Solomon, Shruti H Mehta, Aylur K Srikrishnan, et al.
World Journal of Gastroenterology|August 14, 2025
Poor sleep and hepatic steatosis contribute to poorer quality of life in people with human immunodeficiency virusAna N Hyatt, Sai K Kuchana, Eduardo Vilar-Gomez, et al.
Alimentary Pharmacology & Therapeutics|December 29, 2023
Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United StatesSamer Gawrieh, Eduardo Vilar-Gomez, Tinsay A Woreta, et al.
The New England Journal of Medicine|April 1, 2011
Boceprevir for untreated chronic HCV genotype 1 infectionFred Poordad, Jonathan McCone, Bruce R Bacon, et al.
Pageof 41